Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...
CNBC’s Jim Cramer stresses the importance of investing for the long term, highlighting healthcare stocks Eli Lilly, Merck and ...
Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...
Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Eli Lilly estimates that is about 15-20 million ... Obstructive sleep apnea isn’t just an inconvenience, it’s a serious medical condition that impairs breathing and sleep quality.
Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...
beating the performance of the Medical sector with its loss of 3.78% and the S&P 500's gain of 0.22%. The investment community will be closely monitoring the performance of Eli Lilly in its ...
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback